L3VLUP
ProSign in

XENE in the 13F filings

Xenon Pharmaceuticals Inc · CUSIP 98420N105

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 13 Nov 2023
Managers listing it
7
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 5 listed it in both
Shares listed
6,435,819
combined, among listed positions
Reported value
$220m
combined, at the quarter end

Managers listing XENE in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

7 of 7 holders

ActionFiling
Capital World Investors2,274,974$78munder 0.1%Held013 Nov 2023 (the filing on sec.gov)
Marshall Wace LLP2,154,394$74m0.15%Trimmed-166,02514 Nov 2023 (the filing on sec.gov)
Point72 Asset Management LP1,125,708$38m0.11%Addedn.a.14 Nov 2023 (the filing on sec.gov)
ExodusPoint Capital Management LP359,838$12m0.12%Newnew13 Nov 2023 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC198,984$6.8m0.05%Added+18,84114 Nov 2023 (the filing on sec.gov)
Holocene Advisors LP178,470$6.1munder 0.1%Trimmed-534,00814 Nov 2023 (the filing on sec.gov)
Woodline Partners LP143,451$4.9m0.06%Trimmed-146,94914 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
7 in Q3 2024 to 9 in Q2 2026

Tracked managers listing it, at least.

051015201520162017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
XENE by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20141$12mn.a.n.a.
Q1 20151$11mn.a.n.a.
Q3 20151$8.5mn.a.n.a.
Q4 20151$8.3mn.a.n.a.
Q1 20161$7.2mn.a.n.a.
Q2 20161$6.1mn.a.n.a.
Q3 20161$8.3mn.a.n.a.
Q4 20161$9.4mn.a.n.a.
Q1 20171$5.7mn.a.n.a.
Q2 20172$4.9mn.a.n.a.
Q3 20172$5.0mn.a.n.a.
Q4 20172$5.1mn.a.n.a.
Q1 20182$8.9mn.a.n.a.
Q2 20183$17mn.a.n.a.
Q3 20185$21mn.a.n.a.
Q4 20183$9.5mn.a.n.a.
Q1 20194$24mn.a.n.a.
Q2 20193$19mn.a.n.a.
Q3 20193$17mn.a.n.a.
Q4 20193$25mn.a.n.a.
Q1 20202$18mn.a.n.a.
Q2 20203$21mn.a.n.a.
Q1 20211$14mn.a.n.a.
Q2 20211$17mn.a.n.a.
Q3 20212$20mn.a.n.a.
Q4 20214$205mn.a.n.a.
Q1 20226$215mn.a.n.a.
Q2 20227$230mn.a.n.a.
Q3 20227$330mn.a.n.a.
Q4 20228$303mn.a.n.a.
Q1 20239$259mn.a.n.a.
Q2 20235$222mn.a.n.a.
Q3 20237$220mn.a.n.a.
Q4 202311$590m83
Q1 20246$396m05
Q2 20247$383m32
Q3 20247$428m32
Q4 20246$400m23
Q1 20255$343m22
Q2 20255$224m41
Q3 20255$415m40
Q4 20256$501m1212
Q1 20268$1.3bn229
Q2 20269$1.2bn1715

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

XENE and LLY →XENE and JNJ →XENE and VRTX →Choose a stock to compare with XENE →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own XENE, latest filings →Back to the 13F Explorer →